Effect of active anticancer therapy on serologic response to SARS‐CoV‐2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma

To evaluate the serologic response to the BNT162b2 messenger ribonucleic acid vaccine in patients with urothelial carcinoma and renal cell carcinoma.

[1]  L. Pickering,et al.  Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer , 2022, The Lancet.

[2]  A. Reiner-Benaim,et al.  Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer , 2021, Annals of Oncology.

[3]  R. Grifantini,et al.  Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment , 2021, European Journal of Cancer.

[4]  L. Kadouri,et al.  Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment. , 2021, JAMA oncology.

[5]  A. Iafrate,et al.  Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Robin L. Jones,et al.  Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study , 2021, Nature Cancer.

[7]  G. Ohji,et al.  Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer , 2021, Journal of Infection and Chemotherapy.

[8]  D. Wolf,et al.  Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment , 2021, ESMO Open.

[9]  H. Nishiyama,et al.  Impact of the objective response to and number of cycles of platinum‐based first‐line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab , 2021, International journal of urology : official journal of the Japanese Urological Association.

[10]  H. Nishiyama,et al.  Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. , 2021, Urologic oncology.

[11]  H. Nishiyama,et al.  Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era , 2021, Cancer medicine.

[12]  S. Fafi-Kremer,et al.  Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. , 2021, JAMA.

[13]  K. Ivens,et al.  Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients , 2021, Kidney360.

[14]  H. Nishiyama,et al.  Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR , 2021, Cancer Immunology, Immunotherapy.

[15]  H. Nishiyama,et al.  Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching. , 2021, Journal of geriatric oncology.

[16]  H. Nishiyama,et al.  Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era , 2021, International Journal of Clinical Oncology.

[17]  J. Achard,et al.  Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients , 2021, Journal of the American Society of Nephrology : JASN.

[18]  I. Étienne,et al.  Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients , 2021, Journal of the American Society of Nephrology : JASN.

[19]  T. Tsuzuki,et al.  Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis , 2021, BJU international.

[20]  K. Pradhan,et al.  Seroconversion rates following COVID-19 vaccination among patients with cancer , 2021, Cancer Cell.

[21]  N. Moskovits,et al.  Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer , 2021, JAMA oncology.

[22]  S. Boyd,et al.  Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis , 2021, medRxiv.

[23]  H. Nishiyama,et al.  Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort , 2021, Cancer medicine.

[24]  E. Chamorey,et al.  Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors , 2021, Annals of Oncology.

[25]  A. Kribben,et al.  Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) , 2021, Viruses.

[26]  L. Poon,et al.  Neutralizing antibody titres in SARS-CoV-2 infections , 2021, Nature communications.

[27]  N. Berger,et al.  Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. , 2020, JAMA oncology.

[28]  H. Nishiyama,et al.  Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab , 2020, Cancer science.

[29]  T. Habuchi,et al.  Efficacy and safety of first‐line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study , 2020, International journal of urology : official journal of the Japanese Urological Association.

[30]  H. Haslacher,et al.  Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity , 2020, medRxiv.

[31]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[32]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[33]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.